Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 3
2024 23
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps.
Wu J, Jones N, Chao PH, Chan V, Hohenwarter L, Wu A, Bergamo M, Rodríguez-Rodríguez C, Saatchi K, Liang A, Häfeli UO, Tan Z, Hedtrich S, Andrew LJ, Li SD. Wu J, et al. Biomaterials. 2024 Jul;308:122567. doi: 10.1016/j.biomaterials.2024.122567. Epub 2024 Apr 6. Biomaterials. 2024. PMID: 38603825 Free article.
These effects were superior to those in the protamine formulation group and subcutaneous (s.c.) alphaCD124 given at a 12.5-fold higher dose. Intranasal delivery of protamine, Nano-P, or Dendri-P did not induce any measurable toxicities in mice....
These effects were superior to those in the protamine formulation group and subcutaneous (s.c.) alphaCD124 given at a 12.5-fold highe …
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH; SimpliciTB Consortium. Cevik M, et al. Lancet Infect Dis. 2024 Sep;24(9):1003-1014. doi: 10.1016/S1473-3099(24)00223-8. Epub 2024 May 17. Lancet Infect Dis. 2024. PMID: 38768617 Free article. Clinical Trial.
Median time to negative culture (TTN) was 6 weeks (IQR 4-8) on 4 months of BPaMZ and 11 weeks (6-12) on HRZE. 86% of participants with DR-TB receiving 6 months of BPaMZ (n=152) reached culture-negative status by week 8, with a median TTN of 5 weeks (IQR 3-7). ...It also hi …
Median time to negative culture (TTN) was 6 weeks (IQR 4-8) on 4 months of BPaMZ and 11 weeks (6-12) on HRZE. 86% of participants wit …
K29-linked free polyubiquitin chains affect ribosome biogenesis and direct ribosomal proteins to the intranuclear quality control compartment.
Garadi Suresh H, Bonneil E, Albert B, Dominique C, Costanzo M, Pons C, Masinas MPD, Shuteriqi E, Shore D, Henras AK, Thibault P, Boone C, Andrews BJ. Garadi Suresh H, et al. Mol Cell. 2024 Jun 20;84(12):2337-2352.e9. doi: 10.1016/j.molcel.2024.05.018. Epub 2024 Jun 12. Mol Cell. 2024. PMID: 38870935
These findings reveal the physiological relevance of INQ and provide insights into mechanisms of cellular toxicity associated with ribosomopathies....
These findings reveal the physiological relevance of INQ and provide insights into mechanisms of cellular toxicity associated with ri …
Potential Trypanocidal Activity of Glycerol Analogues.
Humann RA, Smith TK. Humann RA, et al. ChemistryOpen. 2024 Dec;13(12):e202400094. doi: 10.1002/open.202400094. Epub 2024 Sep 12. ChemistryOpen. 2024. PMID: 39263751 Free PMC article.
All four compounds either matched or marginally increased the toxicity of SHAM when used in combination against Trypanosoma brucei. However, the compounds exhibited mostly an antagonistic relationship with SHAM rather than synergistic. ...
All four compounds either matched or marginally increased the toxicity of SHAM when used in combination against Trypanosoma brucei. H …
Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses.
Benson P, Kuretski J, Donovan C, Harper G, Merrill D, Metzner AA, Mycock K, Wallis H, Brogan AP, Patarroyo J, Oglesby A. Benson P, et al. Infect Dis Ther. 2024 Apr;13(4):875-889. doi: 10.1007/s40121-024-00950-1. Epub 2024 Apr 3. Infect Dis Ther. 2024. PMID: 38570444 Free PMC article.
The most common healthcare provider (HCP)-reported reason for initiating DTG/3TC was avoidance of long-term toxicities among individuals in the test-and-treat subgroup. Of 16 treatment-naive individuals with high baseline viral loads (median [IQR] treatment duration, 100,0 …
The most common healthcare provider (HCP)-reported reason for initiating DTG/3TC was avoidance of long-term toxicities among individu …
Vectorized Human Antibody-Mediated Anti-Eosinophil Gene Therapy.
Gioulvanidou M, Sarklioglu S, Chen X, Lebedeva IV, Inalman Y, Pohl MA, Bourne L, Andrew D, Lorenz IC, Stiles KM, Pagovich OE, Hackett NR, Kaminsky SM, de Mulder Rougvie M, Crystal RG. Gioulvanidou M, et al. Hum Gene Ther. 2024 Jan;36(1-2):11-27. doi: 10.1089/hum.2024.165. Epub 2024 Dec 26. Hum Gene Ther. 2024. PMID: 39725494
Chronic hypereosinophilia, defined as persistent elevated blood levels of eosinophils 1,500/muL, is associated with tissue infiltration of eosinophils and consequent organ damage by eosinophil release of toxic mediators. The current therapies for chronic hypereosinophilia …
Chronic hypereosinophilia, defined as persistent elevated blood levels of eosinophils 1,500/muL, is associated with tissue infiltration of e …
The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
Ong WL, Loblaw A. Ong WL, et al. World J Urol. 2023 Dec;41(12):3485-3491. doi: 10.1007/s00345-023-04663-x. Epub 2023 Nov 3. World J Urol. 2023. PMID: 37921936 Review.
PACE-B trial compared 78 Gy in 39-fraction or 62 Gy in 20-fraction vs 36.25 Gy in 5-fraction prostate SBRT, with no significant differences in toxicity outcomes at 2 years. Five-year efficacy data for PACE-B are expected in 2024. Five-fraction prostate SBRT is curre …
PACE-B trial compared 78 Gy in 39-fraction or 62 Gy in 20-fraction vs 36.25 Gy in 5-fraction prostate SBRT, with no significant differences …
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Armstrong AJ, Geva R, Chung HC, Lemech C, Miller WH Jr, Hansen AR, Lee JS, Tsai F, Solomon BJ, Kim TM, Rolfo C, Giranda V, Ren Y, Liu F, Kandala B, Freshwater T, Wang JS. Armstrong AJ, et al. Invest New Drugs. 2024 Feb;42(1):145-159. doi: 10.1007/s10637-023-01410-2. Epub 2024 Feb 7. Invest New Drugs. 2024. PMID: 38324085 Free PMC article. Clinical Trial.
Median progression-free survival was 1.8-2.4 months without evidence of a dose-response relationship, and the study was closed at a prespecified interim analysis for lack of efficacy. Dose-limiting toxicities occurred in 2/48 patients (4%) receiving navarixin 30 mg and 3/4 …
Median progression-free survival was 1.8-2.4 months without evidence of a dose-response relationship, and the study was closed at a prespeci …
A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.
Evans L, Walker R, MacDiarmid J, Brahmbhatt H, Anazodo A, McCowage G, Gifford AJ, Kavallaris M, Trahair T, Ziegler DS. Evans L, et al. Target Oncol. 2024 May;19(3):333-342. doi: 10.1007/s11523-024-01051-2. Epub 2024 Mar 28. Target Oncol. 2024. PMID: 38546944 Free PMC article. Clinical Trial.
RESULTS: EGFR expression was detected in 12 (32%) of the paediatric tumours tested. Nine patients were enrolled and treated on the trial, including three patients with diffuse midline glioma. Overall, (E)EDVs(Mit) was well tolerated, with no dose-limiting toxicities …
RESULTS: EGFR expression was detected in 12 (32%) of the paediatric tumours tested. Nine patients were enrolled and treated on the tr …
Implementation of in situ aerobic cometabolism for groundwater treatment: State of the knowledge and important factors for field operation.
Skinner J, Delgado AG, Hyman M, Chu MJ. Skinner J, et al. Sci Total Environ. 2024 May 15;925:171667. doi: 10.1016/j.scitotenv.2024.171667. Epub 2024 Mar 12. Sci Total Environ. 2024. PMID: 38485017 Free article. Review.
Successful applications of aerobic cometabolic treatment therefore require special considerations beyond conventional in situ bioremediation, such as competitive inhibition between growth-supporting primary substrate(s) and contaminant non-growth substrates, toxic effects …
Successful applications of aerobic cometabolic treatment therefore require special considerations beyond conventional in situ bioremediation …
25 results